Jamie Balderas
Family · Long Beach, CANPI 1861973034
Payments from drug & device makers
Across 167 payments — averaging $39.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AstraZeneca$748
- E.r. Squibb & Sons, L.L.C.$610
- Merck$475
- Dendreon Pharmaceuticals LLC$282
- Incyte Corporation$258
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,31395%
- Education$3285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 42 | $1,621 |
| AstraZeneca(2 entities) | 11 | $748 |
| E.r. Squibb & Sons, L.L.C. | 17 | $610 |
| Merck | 19 | $475 |
| Dendreon Pharmaceuticals LLC | 3 | $282 |
| Incyte Corporation | 6 | $258 |
| Bayer | 4 | $190 |
| Daiichi Sankyo Inc. | 5 | $167 |
| Astellas Pharma US Inc | 3 | $161 |
| Regeneron Healthcare Solutions, Inc. | 2 | $147 |
| Sanofi | 4 | $142 |
| Seagen Inc. | 2 | $140 |
| GSK | 2 | $140 |
| Novartis | 5 | $132 |
| Servier Pharmaceuticals LLC | 1 | $125 |
| Myovant Sciences Inc. | 1 | $120 |
| Tempus AI, Inc | 2 | $118 |
| Pharmaessentia USA Corporation | 1 | $110 |
| Amgen | 5 | $94 |
| Lilly USA, LLC | 4 | $86 |
| Ipsen Biopharmaceuticals, Inc | 3 | $80 |
| Genentech USA, Inc. | 3 | $78 |
| Rigel Pharmaceuticals, Inc. | 3 | $78 |
| Beone Medicines USA, Inc. | 2 | $72 |
| Puma Biotechnology, Inc. | 3 | $64 |
| AbbVie | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $52 |
| Deciphera Pharmaceuticals Inc. | 1 | $48 |
| Coherus Oncology, Inc. | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Karyopharm Therapeutics Inc. | 1 | $31 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Tersera Therapeutics LLC | 1 | $29 |
| Genmab U.S., Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Mirati Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,641 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 31 | $398,828 |
| ErleadaApalutamide | 19 | $264,491 |
| XtandiEnzalutamide | 11 | $146,226 |
| Abiraterone Acetate | 90 | $51,819 |
| EliquisApixaban | 11 | $7,672 |
| XareltoRivaroxaban | 13 | $7,131 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $972 |
| Bicalutamide | 15 | $417 |
| Ondansetron Hcl | 32 | $369 |
| Gabapentin | 33 | $233 |
| Levothyroxine Sodium | 31 | $183 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 22 | $150 |
| Prednisone | 54 | $144 |
| Prochlorperazine Maleate | 12 | $89 |
| Potassium Chloride | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $190 | $398,82831 claims |
| Johnson & JohnsonErleada, Xarelto | $1,621 | $271,62232 claims |
| Astellas Pharma US IncXtandi | $161 | $146,22611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Long Beach
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.